The WHO Classification of Tumors of the Nervous System, Journal of Neuropathology & Experimental Neurology, vol.61, issue.3, pp.215-225, 2002. ,
DOI : 10.1093/jnen/61.3.215
Epidemiology of Brain Tumors, Neurologic Clinics, vol.25, issue.4, pp.867-890, 2007. ,
DOI : 10.1016/j.ncl.2007.07.002
Brain Tumors, New England Journal of Medicine, vol.344, issue.2, pp.114-123, 2001. ,
DOI : 10.1056/NEJM200101113440207
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial, The Lancet Oncology, vol.10, issue.5, pp.459-466, 2009. ,
DOI : 10.1016/S1470-2045(09)70025-7
Microglia: gatekeepers of central nervous system immunology, Journal of Leukocyte Biology, vol.85, issue.3, pp.352-370, 2005. ,
DOI : 10.1189/jlb.0608385
Dendritic cells in the initiation of immune responses against central nervous system-derived antigens, Immunology Letters, vol.92, issue.1-2, pp.107-115, 2004. ,
DOI : 10.1016/j.imlet.2003.10.017
Brain antigens in functionally distinct antigen-presenting cell populations in cervical lymph nodes in MS and EAE, Journal of Molecular Medicine, vol.44, issue.3, pp.273-286, 2009. ,
DOI : 10.1007/s00109-008-0421-4
Immune cell migration as a means to control immune privilege: lessons from the CNS and tumors, Immunological Reviews, vol.99, issue.1, pp.195-212, 2006. ,
DOI : 10.1016/S1471-4906(03)00117-0
Trafficking of immune cells in the central nervous system, Journal of Clinical Investigation, vol.120, issue.5, pp.1368-1379, 2010. ,
DOI : 10.1172/JCI41911
Blood-brain barrier breakdown in septic encephalopathy and brain tumours*, Journal of Anatomy, vol.200, issue.6, pp.639-646, 2002. ,
DOI : 10.1046/j.1469-7580.2002.00065.x
Extracellular matrix and the blood-brain barrier in glioblastoma multiforme: spatial segregation of tenascin and agrin, Acta Neuropathologica, vol.104, issue.1, pp.85-91, 2002. ,
DOI : 10.1007/s00401-002-0524-x
Prolonged Microglial Cell Activation and Lymphocyte Infiltration following Experimental Herpes Encephalitis, The Journal of Immunology, vol.181, issue.9, pp.6417-6426, 2008. ,
DOI : 10.4049/jimmunol.181.9.6417
Effector T cell interactions with meningeal vascular structures in nascent autoimmune CNS lesions, Nature, vol.95, issue.7269, pp.94-98, 2009. ,
DOI : 10.1038/nature08478
Brain Microenvironment Promotes the Final Functional Maturation of Tumor-Specific Effector CD8+ T Cells, The Journal of Immunology, vol.179, issue.2, pp.845-853, 2007. ,
DOI : 10.4049/jimmunol.179.2.845
Adoptive immunotherapy induces CNS dendritic cell recruitment and antigen presentation during clearance of a persistent viral infection, The Journal of Experimental Medicine, vol.67, issue.8, pp.1963-1975, 2006. ,
DOI : 10.1016/S0092-8674(02)01139-X
Expression of nine tumour antigens in a series of human glioblastoma multiforme: interest of EGFRvIII, IL-13R??2, gp100 and TRP-2 for immunotherapy, Journal of Neuro-Oncology, vol.2, issue.2, pp.139-148, 2007. ,
DOI : 10.1007/s11060-006-9220-3
Immunotherapeutic Approaches for Glioma, Critical Reviews??? in Immunology, vol.29, issue.1, pp.1-42, 2009. ,
DOI : 10.1615/CritRevImmunol.v29.i1.10
Spontaneous immune responses against glioma-associated antigens in a long term survivor with malignant glioma, Journal of Translational Medicine, vol.5, issue.1, 2007. ,
DOI : 10.1186/1479-5876-5-68
Elevated HLA-E levels in human glioblastomas but not in grade I to III astrocytomas correlate with infiltrating CD8+ cells, 14 Clinical and Developmental Immunology [21], pp.50-58, 2007. ,
DOI : 10.1016/j.jneuroim.2007.07.002
Preferential In Situ CD4+CD56+ T Cell Activation and Expansion within Human Glioblastoma, The Journal of Immunology, vol.180, issue.11, pp.7673-7680, 2008. ,
DOI : 10.4049/jimmunol.180.11.7673
Interleukin-2 and autologous lymphokine-activated killer cells in the treatment of malignant glioma, Journal of Neurosurgery, vol.64, issue.5, pp.2101-2104, 1986. ,
DOI : 10.3171/jns.1986.64.5.0743
Adoptive immunotherapy for recurrent glioblastoma multiforme using lymphokine activated killer cells and recombinant interleukin-2, Cancer, vol.47, issue.4, pp.665-671, 1988. ,
DOI : 10.1002/1097-0142(19880815)62:4<665::AID-CNCR2820620403>3.0.CO;2-O
Intratumoral LAK cell and interleukin-2 therapy of human gliomas, Journal of Neurosurgery, vol.70, issue.2, pp.175-182, 1989. ,
DOI : 10.3171/jns.1989.70.2.0175
Long-Term Follow-up of Patients with Recurrent Malignant Gliomas Treated with Adjuvant Adoptive Immunotherapy, Neurosurgery, vol.28, issue.1, pp.16-23, 1991. ,
DOI : 10.1227/00006123-199101000-00003
Therapy of recurrent high grade gliomas with surgery, and autologous mitogen activated IL-2 stimulated killer (MAK) Lymphocytes: I. Enhancement of MAK lytic activity and cytokine production by PHA and clinical use of PHA, Journal of Neuro-Oncology, vol.123, issue.2, pp.141-155, 1993. ,
DOI : 10.1007/BF01053935
Local immunotherapy of recurrent glioblastoma multiforme by intracerebral perfusion of interleukin-2 and LAK cells, European Cytokine Network, vol.4, issue.5, pp.331-341, 1993. ,
Loco-regional immunotherapy with recombinant interleukin-2 and adherent lymphokine-activated killer cells (A-LAK) in recurrent glioblastoma patients, Cancer Immunology Immunotherapy, vol.51, issue.3, pp.193-197, 1994. ,
DOI : 10.1007/BF01533386
Improved long term survival after intracavitary interleukin-2 and lymphokine-activated killer cells for adults with recurrent malignant glioma, Cancer, vol.53, issue.5, pp.840-852, 1995. ,
DOI : 10.1002/1097-0142(19950901)76:5<840::AID-CNCR2820760519>3.0.CO;2-R
Adoptive immimotherapy using lymphokine-activated killer (LAK) cells and interleukin-2 for recurrent malignant primary brain tumors, Journal of Neuro-Oncology, vol.27, issue.2, pp.133-140, 1995. ,
Adoptive cellular immunotherapy for the treatment of malignant gliomas, Critical Reviews in Oncology/Hematology, vol.39, issue.1-2, pp.31-42, 2001. ,
DOI : 10.1016/S1040-8428(01)00122-6
Intracavitary Placement of Autologous Lymphokine-Activated Killer (LAK) Cells after Resection of Recurrent Glioblastoma, Journal of Immunotherapy, vol.27, issue.5, pp.398-404, 2004. ,
DOI : 10.1097/00002371-200409000-00009
Intralesional Lymphokine-activated Killer Cells as Adjuvant Therapy for Primary Glioblastoma, Journal of Immunotherapy, vol.32, issue.9, pp.914-919, 2009. ,
DOI : 10.1097/CJI.0b013e3181b2910f
Establishment of interleukin 2 dependent cytotoxic T lymphocyte cell line specific for autologous brain tumor and its intracranial administration for therapy of the tumor, Journal of Neuro-Oncology, vol.4, issue.4, pp.329-336, 1987. ,
DOI : 10.1007/BF00195603
Reduction of End-stage Malignant Glioma by Injection with Autologous Cytotoxic T Lymphocytes, Japanese Journal of Cancer Research, vol.76, issue.5, pp.536-545, 1999. ,
DOI : 10.1111/j.1349-7006.1999.tb00781.x
Effects of local injection of ex vivo expanded autologous tumor-specific T lymphocytes in cases with recurrent malignant gliomas, Clinical Cancer Research, vol.9, issue.9, pp.3294-3302, 2003. ,
Treatment of recurrent glioma with intracavitary alloreactive cytotoxic T lymphocytes and interleukin-2, Cancer Immunology, Immunotherapy, vol.45, issue.2, pp.77-87, 1997. ,
DOI : 10.1007/s002620050405
Pilot study of local autologous tumor infiltrating lymphocytes for the treatment of recurrent malignant gliomas, Journal of Neuro-Oncology, vol.45, issue.2, pp.141-157, 1999. ,
DOI : 10.1023/A:1006293606710
Autologous tumor cell vaccination combined with adoptive cellular immunotherapy in patients with Grade III/IV astrocytoma, Journal of Neuro-Oncology, vol.27, issue.2, pp.179-189, 1996. ,
DOI : 10.1007/BF00177482
Systemic T cell adoptive immunotherapy of malignant gliomas, Journal of Neurosurgery, vol.89, issue.1, pp.42-51, 1998. ,
DOI : 10.3171/jns.1998.89.1.0042
T cell adoptive immunotherapy of newly diagnosed gliomas, Clinical Cancer Research, vol.6, issue.6, pp.2209-2218, 2000. ,
A pilot study of autologous cancer cell vaccination and cellular immunotherapy using anti-CD3 stimulated lymphocytes in patients with recurrent grade III/IV astrocytoma, Journal of Neuro-Oncology, vol.48, issue.2, pp.113-120, 2000. ,
DOI : 10.1023/A:1006456421177
Adoptive immunotherapy in patients with recurrent malignant glioma: preliminary results of using autologous whole-tumor vaccine plus granulocyte-macrophage colony???stimulating factor and adoptive transfer of anti-CD3???activated lymphocytes, Neurosurgical Focus, vol.9, issue.6, p.9, 2000. ,
DOI : 10.3171/foc.2000.9.6.10
Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients, Annals of Oncology, vol.18, issue.2, pp.226-232, 2007. ,
DOI : 10.1093/annonc/mdl158
Interleukin-2 gene therapy in a patient with glioblastoma, Gene Therapy, vol.2, issue.2, pp.164-167, 1995. ,
Preliminary results of active specific immunization with modified tumor cell vaccine in glioblastoma multiforme, Journal of Neuro-Oncology, vol.53, issue.1, pp.39-46, 2001. ,
DOI : 10.1023/A:1011856406683
Results of a Pilot Study Involving the Use of an Antisense Oligodeoxynucleotide Directed Against the Insulin-Like Growth Factor Type I Receptor in Malignant Astrocytomas, Journal of Clinical Oncology, vol.19, issue.8, pp.2189-2200, 2001. ,
DOI : 10.1200/JCO.2001.19.8.2189
Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of recurrent glioblastoma: Preliminary observations in a patient with a favorable Clinical and Developmental Immunology 15 ,
Antitumor Vaccination of Patients With Glioblastoma Multiforme: A Pilot Study to Assess Feasibility, Safety, and Clinical Benefit, Journal of Clinical Oncology, vol.22, issue.21, pp.4272-4281, 2004. ,
DOI : 10.1200/JCO.2004.09.038
Technical hurdles in a pilot clinical trial of combined B7-2 and GM-CSF immunogene therapy for glioblastomas and melanomas, Journal of Neuro-Oncology, vol.7, issue.2, pp.71-80, 2006. ,
DOI : 10.1007/s11060-005-9058-0
Clinical trial of autologous formalin-fixed tumor vaccine for glioblastoma multiforme patients, Cancer Science, vol.174, issue.8, pp.1226-1233, 2007. ,
DOI : 10.1016/j.ijrobp.2004.04.046
Autologous tumor cell vaccination plus infusion of GM-CSF by a programmable pump in the treatment of recurrent malignant gliomas, Journal of Clinical Neuroscience, vol.17, issue.7, pp.842-848, 2010. ,
DOI : 10.1016/j.jocn.2009.11.017
Treatment of a patient by vaccination with autologous dendritic cells pulsed with allogeneic major histocompatibility complex class Imatched tumor peptides. Case report, Neurosurgical Focus, vol.9, issue.6, p.8, 2000. ,
Results of a phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells, Cancer Immunology, Immunotherapy, vol.50, issue.7, pp.337-344, 2001. ,
DOI : 10.1007/s002620100205
Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration, Cancer Research, vol.61, issue.3, pp.842-847, 2001. ,
Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: results of a clinical phase I/II trial, British Journal of Cancer, vol.89, issue.7, pp.1172-1179, 2003. ,
DOI : 10.1038/sj.bjc.6601268
Transient local response and persistent tumor control in a child with recurrent malignant glioma: treatment with combination therapy including dendritic cell therapy, Journal of Neurosurgery: Pediatrics, vol.100, issue.5, pp.492-497, 2004. ,
DOI : 10.3171/ped.2004.100.5.0492
Vaccination with Tumor Lysate-Pulsed Dendritic Cells Elicits Antigen-Specific, Cytotoxic T-Cells in Patients with Malignant Glioma, Cancer Research, vol.64, issue.14, pp.4973-4979, 2004. ,
DOI : 10.1158/0008-5472.CAN-03-3505
Results of a phase 1 study utilizing monocyte-derived dendritic cells pulsed with tumor RNA in children and young adults with brain cancer, Neuro-Oncology, vol.6, issue.3, pp.236-246, 2004. ,
DOI : 10.1215/S1152851703000668
Surgery and adjuvant dendritic cell-based tumour vaccination for patients with relapsed malignant glioma, a feasibility study, British Journal of Cancer, vol.61, issue.9, pp.1656-1662, 2004. ,
DOI : 10.1038/sj.bjc.6602195
Clinical Responsiveness of Glioblastoma Multiforme to Chemotherapy after Vaccination, Clinical Cancer Research, vol.10, issue.16, pp.5316-5326, 2004. ,
DOI : 10.1158/1078-0432.CCR-04-0497
Vaccination of Glioma Patients with Fusions of Dendritic and Glioma Cells and Recombinant Human Interleukin 12, Journal of Immunotherapy, vol.27, issue.6, pp.452-459, 2004. ,
DOI : 10.1097/00002371-200411000-00005
Dendritic Cell Vaccination in Glioblastoma Patients Induces Systemic and Intracranial T-cell Responses Modulated by the Local Central Nervous System Tumor Microenvironment, Clinical Cancer Research, vol.11, issue.15, pp.5515-5525, 2005. ,
DOI : 10.1158/1078-0432.CCR-05-0464
Clinical Evaluation of Dendritic Cell Vaccination for Patients with Recurrent Glioma: Results of a Clinical Phase I/II Trial, Clinical Cancer Research, vol.11, issue.11, pp.4160-4167, 2005. ,
DOI : 10.1158/1078-0432.CCR-05-0120
Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of patients with malignant gliomas, Journal of Translational Medicine, vol.5, issue.1, 2007. ,
DOI : 10.1186/1479-5876-5-67
Results of a phase I dendritic cell vaccine trial for malignant astrocytoma: potential interaction with adjuvant chemotherapy, Journal of Clinical Neuroscience, vol.15, issue.2, pp.114-121, 2008. ,
DOI : 10.1016/j.jocn.2007.08.007
Vaccination Elicits Correlated Immune and Clinical Responses in Glioblastoma Multiforme Patients, Cancer Research, vol.68, issue.14, pp.5955-5964, 2008. ,
DOI : 10.1158/0008-5472.CAN-07-5973
Postoperative Adjuvant Dendritic Cell-Based Immunotherapy in Patients with Relapsed Glioblastoma Multiforme, Clinical Cancer Research, vol.14, issue.10, pp.3098-3104, 2008. ,
DOI : 10.1158/1078-0432.CCR-07-4875
An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme, Molecular Cancer Therapeutics, vol.8, issue.10, pp.2773-2779, 2009. ,
DOI : 10.1158/1535-7163.MCT-09-0124
Adjuvant dendritic cell-based tumour vaccination for children with malignant brain tumours, Pediatric Blood & Cancer, vol.49, issue.4, pp.519-525, 2010. ,
DOI : 10.1002/pbc.22319
Integration of autologous dendritic cell-based immunotherapy in the primary treatment for patients with newly diagnosed glioblastoma multiforme: a pilot study, Journal of Neuro-Oncology, vol.24, issue.2, pp.261-272, 2010. ,
DOI : 10.1007/s11060-010-0131-y
Cancer immunotherapy: moving beyond current vaccines, Nature Medicine, vol.8, issue.9, pp.909-915, 2004. ,
DOI : 10.1002/1097-0215(20001015)88:2<232::AID-IJC14>3.3.CO;2-#
Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group, Journal of Clinical Oncology, vol.28, issue.11, pp.1963-1972, 2010. ,
DOI : 10.1200/JCO.2009.26.3541
Malignant glioma: ESMO clinical recommendations for diagnosis, treatment and follow-up, Annals of Oncology, vol.20, pp.126-128, 2009. ,
Oncological patterns of care and outcome for 952 patients with newly diagnosed glioblastoma in, Journal of Neurooncology. In press. Clinical and Developmental Immunology, 2004. ,
MGMT promoter methylation in malignant gliomas: ready for personalized medicine?, Nature Reviews Neurology, vol.113, issue.1, pp.39-51, 2010. ,
DOI : 10.1038/nrneurol.2009.197
Prognostic value of O6-methylguanine-DNA methyltransferase status in glioblastoma patients, assessed by five different methods, Journal of Neuro-Oncology, vol.16, issue.3, pp.311-322, 2010. ,
DOI : 10.1007/s11060-009-0031-1
URL : https://hal.archives-ouvertes.fr/inserm-00435222
Irradiated tumor cell vaccine for treatment of an established glioma. I. Successful treatment with combined radiotherapy and cellular vaccination, Cancer Immunology, Immunotherapy, vol.51, issue.4, pp.179-189, 2002. ,
Active immunotherapy for advanced intracranial murine tumors by using dendritic cell-tumor cell fusion vaccines, Journal of Neurosurgery, vol.103, issue.1, pp.156-164, 2005. ,
DOI : 10.3171/jns.2005.103.1.0156
Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy, The Journal of Experimental Medicine, vol.123, issue.5, pp.1259-1271, 2006. ,
DOI : 10.1126/science.274.5284.94
Treg depletion with a low-dose metronomic temozolomide regimen in a rat glioma model, Cancer Immunology, Immunotherapy, vol.118, issue.6, pp.1627-1634, 2009. ,
DOI : 10.1007/s00262-009-0671-1
Immunological Factors Relating to the Antitumor Effect of Temozolomide Chemoimmunotherapy in a Murine Glioma Model, Clinical and Vaccine Immunology, vol.17, issue.1, pp.143-153, 2010. ,
DOI : 10.1128/CVI.00292-09
Preferential migration of regulatory T cells mediated by glioma-secreted chemokines can be blocked with chemotherapy, Cancer Immunology, Immunotherapy, vol.36, issue.1, pp.123-131, 2008. ,
DOI : 10.1007/s00262-007-0336-x
Systemic immune suppression in glioblastoma: the interplay between CD14+HLA-DRlo/neg monocytes, tumor factors, and dexamethasone, Neuro-Oncology, vol.12, issue.7 ,
DOI : 10.1093/neuonc/noq001
Adoptive cell therapy for the treatment of patients with metastatic melanoma, Current Opinion in Immunology, vol.21, issue.2, pp.233-240, 2009. ,
DOI : 10.1016/j.coi.2009.03.002
Engineering lymphocyte subsets: tools, trials and tribulations, Nature Reviews Immunology, vol.112, issue.10, pp.704-716, 2009. ,
DOI : 10.1038/nri2635
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3412112
T Cells, The Journal of Experimental Medicine, vol.6, issue.4, pp.569-580, 2003. ,
DOI : 10.1097/00002371-199601000-00009
Changes in the Immunologic Phenotype of Human Malignant Glioma Cells after Passaging in Vitro, Clinical Immunology, vol.102, issue.1, pp.84-95, 2002. ,
DOI : 10.1006/clim.2001.5152
MIP-1?? Antagonizes the Effect of a GM-CSF-Enhanced Subcutaneous Vaccine in a Mouse Glioma Model, Journal of Neuro-Oncology, vol.66, issue.1/2, pp.147-154, 2004. ,
DOI : 10.1023/B:NEON.0000013497.04322.fc
Effects of Combined Granulocyte???Macrophage Colony-Stimulating Factor (GM-CSF), Interleukin-2, and Interleukin-12 based Immunotherapy against Intracranial Glioma in the Rat, Journal of Neuro-Oncology, vol.66, issue.1/2, pp.39-49, 2004. ,
DOI : 10.1023/B:NEON.0000013477.94568.0f
Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma, Proceedings of the National Academy of Sciences, vol.95, issue.22, pp.13141-13146, 1998. ,
DOI : 10.1073/pnas.95.22.13141
Effect of Granulocyte/Macrophage Colony-Stimulating Factor on Vaccination with an Allogeneic Whole-Cell Melanoma Vaccine, Clinical Cancer Research, vol.15, issue.22, pp.7029-7035, 2009. ,
DOI : 10.1158/1078-0432.CCR-09-1540
Effect of Granulocyte/Macrophage Colony-Stimulating Factor on Circulating CD8+ and CD4+ T-Cell Responses to a Multipeptide Melanoma Vaccine: Outcome of a Multicenter Randomized Trial, Clinical Cancer Research, vol.15, issue.22, pp.7036-7044, 2009. ,
DOI : 10.1158/1078-0432.CCR-09-1544
Tumor-Induced Tolerance and Immune Suppression Depend on the C/EBP?? Transcription Factor, Immunity, vol.32, issue.6, pp.790-802, 2010. ,
DOI : 10.1016/j.immuni.2010.05.010
Clinical Considerations in Developing Dendritic Cell Vaccine Based Immunotherapy Protocols in Cancer, Current Molecular Medicine, vol.9, issue.6, pp.725-731, 2009. ,
DOI : 10.2174/156652409788970689
Dendritic cell-based therapeutic cancer vaccines: what we have and what we need, Future Oncology, vol.5, issue.3, pp.379-390, 2009. ,
DOI : 10.2217/fon.09.6
DC-based cancer vaccines, Journal of Clinical Investigation, vol.117, issue.5, pp.1195-1203, 2007. ,
DOI : 10.1172/JCI31205
Dendritic Cell Therapy of High-Grade Gliomas, Brain Pathology, vol.15, issue.4, pp.694-712, 2009. ,
DOI : 10.1111/j.1750-3639.2009.00316.x
Dendritic cell vaccines to combat glioblastoma, Expert Review of Neurotherapeutics, vol.10, issue.4, pp.483-486, 2010. ,
DOI : 10.1586/ern.10.26
Dendritic-cell- and peptide-based vaccination strategies for glioma, Neurosurgical Review, vol.23, issue.6, pp.265-273, 2009. ,
DOI : 10.1007/s10143-009-0189-1
Targeting brain-tumor stem cells, Nature Biotechnology, vol.12, issue.2, pp.193-194, 2007. ,
DOI : 10.1038/nbt0207-193
HER2-Specific T Cells Target Primary Glioblastoma Stem Cells and Induce Regression of Autologous Experimental Tumors, Clinical Cancer Research, vol.16, issue.2, pp.474-485, 2010. ,
DOI : 10.1158/1078-0432.CCR-09-1322
??-Type-1 Polarized Dendritic Cells: A Novel Immunization Tool with Optimized CTL-inducing Activity, Cancer Research, vol.64, issue.17, pp.5934-5937, 2004. ,
DOI : 10.1158/0008-5472.CAN-04-1261
Effective Immunotherapy against Murine Gliomas Using Type 1 Polarizing Dendritic Cells--Significant Roles of CXCL10, Cancer Research, vol.69, issue.4, pp.1587-1595, 2009. ,
DOI : 10.1158/0008-5472.CAN-08-2915
Sipuleucel-T, Nature Reviews Drug Discovery, vol.28, issue.7, pp.513-514, 2010. ,
DOI : 10.1038/nrd3220
Biodistribution of radiolabelled human dendritic cells injected by various routes, European Journal of Nuclear Medicine and Molecular Imaging, vol.198, issue.7, pp.731-741, 2005. ,
DOI : 10.1007/s00259-005-1825-9
Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy, Nature Biotechnology, vol.37, issue.11, pp.1407-1413, 2005. ,
DOI : 10.1002/mrm.1153
Limited Amounts of Dendritic Cells Migrate into the T-Cell Area of Lymph Nodes but Have High Immune Activating Potential in Melanoma Patients, Clinical Cancer Research, vol.15, issue.7, pp.2531-2540, 2009. ,
DOI : 10.1158/1078-0432.CCR-08-2729
Intra-tumoral dendritic cells increase efficacy of peripheral vaccination by modulation of glioma microenvironment, Neuro-Oncology, vol.12, issue.4, pp.377-388, 2010. ,
DOI : 10.1093/neuonc/nop024
T cell receptor-mediated signaling is defective in T cells obtained from patients with primary intracranial tumors, Journal of Immunology, vol.159, issue.9, pp.4415-4425, 1997. ,
Immune defects observed in patients with primary malignant brain tumors, Journal of Neuroimmunology, vol.100, issue.1-2, pp.216-232, 1999. ,
DOI : 10.1016/S0165-5728(99)00203-9
Increased Regulatory T-Cell Fraction Amidst a Diminished CD4 Compartment Explains Cellular Immune Defects in Patients with Malignant Glioma, Cancer Research, vol.66, issue.6, pp.3294-3302, 2006. ,
DOI : 10.1158/0008-5472.CAN-05-3773
Innate immune functions of microglia isolated from human glioma patients, Journal of Translational Medicine, vol.4, 2006. ,
Diminished monocytic HLA-DR expression and ex vivo cytokine secretion capacity in patients with glioblastoma: Effect of tumor extirpation, Journal of Neuroimmunology, vol.84, issue.2, pp.164-171, 1998. ,
DOI : 10.1016/S0165-5728(97)00236-1
Human gliomainduced immunosuppression involves soluble factor(s) that alters monocyte cytokine profile and surface markers, Journal of Immunology, vol.162, issue.8, pp.4882-4892, 1999. ,
Defective Receptor Expression and Dendritic Cell Differentiation of Monocytes in Glioblastomas, Neurosurgery, vol.59, issue.4, pp.902-909, 2006. ,
DOI : 10.1227/01.NEU.0000233907.03070.7B
Immunosuppression and transforming growth factor-? in glioblastoma. Preferential production of transforming growth factor-?2, Journal of Immunology, vol.143, issue.10, pp.3222-3229, 1989. ,
2, Journal of Neurosurgery, vol.71, issue.2, pp.211-217, 1989. ,
DOI : 10.3171/jns.1989.71.2.0211
- and cAMP-modulating agents on human glioblastoma cell killing by interleukin-2-activated lymphocytes, Journal of Neurosurgery, vol.72, issue.4, pp.619-625, 1990. ,
DOI : 10.3171/jns.1990.72.4.0619
Malignant glioma modulation of immune function: relative contribution of different soluble factors, Journal of Neuroimmunology, vol.33, issue.2, pp.89-96, 1991. ,
DOI : 10.1016/0165-5728(91)90052-9
Human Glioma-derived Interleukin-10 Inhibits Antitumor Immune Responses In Vitro, Neurosurgery, vol.37, issue.6, pp.1160-1166, 1995. ,
DOI : 10.1227/00006123-199512000-00016
Identification of CD70-mediated apoptosis of immune effector cells as a novel immune escape pathway of human glioblastoma, Cancer Research, vol.62, issue.9, pp.2592-2599, 2002. ,
Glioblastomas Induce T-Lymphocyte Death by Two Distinct Pathways Involving Gangliosides and CD70, Cancer Research, vol.65, issue.12, pp.5428-5438, 2005. ,
DOI : 10.1158/0008-5472.CAN-04-4395
Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain?, Journal of Clinical Investigation, vol.99, issue.6, pp.1173-1178, 1997. ,
DOI : 10.1172/JCI119273
CD95-Dependent T-Cell Killing by Glioma Cells Expressing CD95 Ligand: More on Tumor Immune Escape, the CD95 Counterattack, and the Immune Privilege of the Brain, Cellular Physiology and Biochemistry, vol.7, issue.5, pp.282-288, 1997. ,
DOI : 10.1159/000154883
Role of Fas ligand (CD95L) in immune escape: the tumor cell strikes back, Journal of Immunology, vol.158, issue.10, pp.4521-4524, 1997. ,
A Functional Role of HLA-G Expression in Human Gliomas: An Alternative Strategy of Immune Escape, The Journal of Immunology, vol.168, issue.9, pp.4772-4780, 2002. ,
DOI : 10.4049/jimmunol.168.9.4772
Expression of the B7-related molecule B7-H1 by glioma cells: a potential mechanism of immune paralysis, Cancer Research, vol.63, issue.21, pp.7462-7467, 2003. ,
B7-homolog 1 expression by human glioma: a new mechanism of immune evasion, NeuroReport, vol.16, issue.10, pp.1081-1085, 2005. ,
DOI : 10.1097/00001756-200507130-00010
Distinct effects of human glioblastoma immunoregulatory molecules programmed cell death ligand-1 (PDL-1) and indoleamine 2,3-dioxygenase (IDO) on tumour-specific T cell functions, Journal of Neuroimmunology, vol.225, issue.1-2, pp.22-33, 2010. ,
DOI : 10.1016/j.jneuroim.2010.04.003
URL : https://hal.archives-ouvertes.fr/inserm-00486777
Inhibition of indoleamine 2,3-dioxygenase activity in IFN-?? stimulated astroglioma cells decreases intracellular NAD levels, Biochemical Pharmacology, vol.66, issue.6, pp.1033-1036, 2003. ,
DOI : 10.1016/S0006-2952(03)00464-7
Indoleamine 2,3-dioxygenase as a new target for malignant glioma therapy, Journal of Neurosurgery, vol.111, issue.2, pp.230-237, 2009. ,
DOI : 10.3171/2008.10.JNS081141
The failure of current immunotherapy for malignant glioma. Tumor-derived TGF-?, T-cell apoptosis, and the immune privilege of the brain, Brain Research Reviews, vol.21, issue.2, pp.128-151, 1995. ,
DOI : 10.1016/0165-0173(95)00010-0
An increase in CD4+CD25+FOXP3+ regulatory T cells in tumor-infiltrating lymphocytes of human glioblastoma multiforme, Neuro-Oncology, vol.8, issue.3, pp.234-243, 2006. ,
DOI : 10.1215/15228517-2006-006
Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: Case study, Clinical and Developmental Immunology, pp.98-103, 2008. ,
DOI : 10.1215/15228517-2007-046
Myeloid-derived suppressor cells as regulators of the immune system, Nature Reviews Immunology, vol.172, issue.3, pp.162-174, 2009. ,
DOI : 10.1038/nri2506
Overexpression of septin 7 suppresses glioma cell growth, Journal of Neuro-Oncology, vol.130, issue.5, pp.329-340, 2010. ,
DOI : 10.1007/s11060-009-0092-1
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma, New England Journal of Medicine, vol.363, issue.8, pp.711-723, 2010. ,
DOI : 10.1056/NEJMoa1003466
Dendritic Cell Vaccination Combined with CTLA4 Blockade in Patients with Metastatic Melanoma, Clinical Cancer Research, vol.15, issue.19, pp.6267-6276, 2009. ,
DOI : 10.1158/1078-0432.CCR-09-1254
CD4+CD25+ regulatory T???cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative, European Journal of Immunology, vol.34, issue.2, pp.336-344, 2004. ,
DOI : 10.1002/eji.200324181
Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines, Blood, vol.112, issue.3, pp.610-618, 2008. ,
DOI : 10.1182/blood-2008-01-135319
Systemic Inhibition of Transforming Growth Factor-?? in Glioma-Bearing Mice Improves the Therapeutic Efficacy of Glioma-Associated Antigen Peptide Vaccines, Clinical Cancer Research, vol.15, issue.21, pp.6551-6559, 2009. ,
DOI : 10.1158/1078-0432.CCR-09-1067
DC vaccination with anti-CD25 treatment leads to long-term immunity against experimental glioma, Neuro-Oncology, vol.11, issue.5, pp.529-542, 2009. ,
DOI : 10.1215/15228517-2009-004